

S 1327

SALTS Act

Congress: 114 (2015–2017, Ended)

Chamber: Senate

Policy Area: Crime and Law Enforcement

Introduced: May 13, 2015

Current Status: Read twice and referred to the Committee on the Judiciary.

Latest Action: Read twice and referred to the Committee on the Judiciary. (May 13, 2015)

Official Text: <https://www.congress.gov/bill/114th-congress/senate-bill/1327>

Sponsor

Name: Sen. Klobuchar, Amy [D-MN]

Party: Democratic • **State:** MN • **Chamber:** Senate

Cosponsors (7 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Feinstein, Dianne [D-CA]	D · CA		May 13, 2015
Sen. Graham, Lindsey [R-SC]	R · SC		May 13, 2015
Sen. Grassley, Chuck [R-IA]	R · IA		May 13, 2015
Sen. Blumenthal, Richard [D-CT]	D · CT		Jul 11, 2016
Sen. Tillis, Thomas [R-NC]	R · NC		Jul 11, 2016
Sen. Cornyn, John [R-TX]	R · TX		Sep 26, 2016
Sen. Whitehouse, Sheldon [D-RI]	D · RI		Sep 26, 2016

Committee Activity

Committee	Chamber	Activity	Date
Judiciary Committee	Senate	Referred To	May 13, 2015

Subjects & Policy Tags

Policy Area:

Crime and Law Enforcement

Related Bills

Bill	Relationship	Last Action
114 HR 1186	Related bill	Mar 31, 2015: Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.

Synthetic Abuse and Labeling of Toxic Substances Act of 2015 or the SALTS Act

Amends the Controlled Substances Act to authorize evidence related to the following factors to be considered in determining whether a controlled substance analogue was intended for human consumption:

- the marketing, advertising, and labeling of the substance;
- the known efficacy or usefulness of the substance for the marketed, advertised, or labeled purpose;
- the difference between the price at which the substance is sold and the price at which the substance it is purported to be or advertised as is normally sold;
- the diversion of the substance from legitimate channels and the clandestine importation, manufacture, or distribution of the substance; and
- whether the defendant knew or should have known that the substance was intended to be consumed by injection, inhalation, ingestion, or any other immediate means.

Declares that the existence of evidence that a substance was not marketed, advertised, or labeled for human consumption shall not preclude the government from establishing, based on all the evidence, that the substance was intended for human consumption.

Actions Timeline

- **May 13, 2015:** Introduced in Senate
- **May 13, 2015:** Read twice and referred to the Committee on the Judiciary.